On 2 August, 2021, the US Food and Drug Administration (FDA) approved a new drug, anifrolumab, for the treatment of systemic lupus erythematosus (SLE, or lupus). Remarkably, this is only the second drug approved for lupus in the past 60 years.
Disclosure: Professor Eric Morand has received funding from AstraZeneca as a consultant and for research support.